Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Injectable microspheres for dermal augmentation and tissue bulking

a technology of dermal augmentation and microspheres, which is applied in the direction of prosthesis, drug compositions, synthetic polymeric active ingredients, etc., can solve the problems of resistance to treatment, severe symptoms, and failure of both methods, and achieve the effect of preventing or reducing the effect of inflammation

Inactive Publication Date: 2004-05-20
BIOSPHERE MEDICAL INC
View PDF22 Cites 69 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0048] It should be recognized that both treatments for GERD, urinary incontinence, urinary reflux disease, and skin deficiencies described above can be used in combination with conventional therapies now used to treat these diseases or conditions i.e., oral diuretics, antacids, suitable drug therapy, cometic surgeries and the like. Such combination therapy can lead to a faster, safer and more comfortable recovery for the patient.
[0051] The microspheres of the present invention also comprise particles that are "hydrophilic," which, as used in the invention, means the particles can dissolve in, absorb, or mix easily with water or aqueous solution.

Problems solved by technology

Although gastroesophageal reflux is a normal physiological phenomenon, in some cases it is a pathophysiological situation that can result in a variety of symptoms which may become severe in extreme cases.
Ulcerative situations not only lead to complications, but they are also more resistant to treatments.
Both methods have been unsuccessful, however, as these materials migrate over time from the initial site of implantation.
However, fundoplication surgery carries the risk of serious side effects and is only marginally successful in curing GERD.
Urinary incontinence is a prevalent problem that affects people of all ages and levels of physical health, both in the community at large and in healthcare settings.
Economically, the costs are astounding; in the United States alone, over ten billion dollars per year is spent managing incontinence.
Often, however, such drug therapies do not achieve complete success with all classes of incontinent patients, and often results in the patient experiencing significant side effects.
While endoscopically directed injections of collagen around the bladder neck has a quite high success rate in sphincter deficiency with no significant morbidity, the use of collagen can result in failures that occur after an average of two years and considerations need to be given to its cost effectiveness (Khullar V. et al., British J. Obstetrics & Gynecology, 104:96-99 (1996)).
Despite of the limited success rate, transurethral collagen injection therapy remains an acceptable treatment for intrinsic sphincter deficiency, due to the lack other suitable alternatives.
When urine goes up from the bladder to the kidneys, it can result in health problems for the person.
Urinary reflux can lead to kidney damage.
Refluxing urine can carry bacteria to the kidney, where it can cause kidney infection.
The combination of reflux and infection can lead to areas of permanent kidney damage or "renal scarring."
If it is extensive enough, the scarring can lead to loss of function of one or both kidneys.
Both methods, however, have drawbacks.
Long term use of antibiotics may cause unpredictable side effects and surgical procedures involve unnecessary risks.
Even though many urinary reflux disease will go away on its own in children, some cases often lead to severe kidney and urinary tract infections and even total kidney failure.
Damage to the skin due to aging, environmental exposure to the sun and other elements, weight loss, child bearing, disease such as acne and cancer, and surgery often results in skin contour deficiencies and other skin anomalies.
Cosmetic surgery, however, has several drawbacks, in addition to the high cost associated with it.
It is usually an invasive and risky procedure, having the potential of leaving scars in areas of operation and affecting normal biological and physiological functions.
Furthermore, cosmetic surgery is often a limited option, available only for certain skin deficiencies.
Even more alarming from a cosmetic perspective, collagen may move from the initial site of injection, causing unsightly bumps and bulges under the skin at undesired locations.
However, due to long term side effects, such as nodules, recurring cellulitis, and skin ulcers, the use of injectable silicone is on the decline.
Further, direct implantation of cells into living tissues such as brain or liver to correct specific deficiencies has been attempted albeit with a number of failures.
The major problems associated with direct cell transplantation are the long term viability of the cell transplant and the immunopathological as well as histological responses.
Most of cell implant results have been, however, largely disappointing for the designated functions (or have had low levels of biological function).
For example, carbon particles, silicone particles, TEFLON paste, collagen beads and polymethylmethacrylate spheres, have been used with disappointing results due to, inter alia, adverse tissue reactions, biological degradation and migration from the initial implantation location.
The problems associated with rigid and non-deformable particles, such as carbon particles and silicone particles, in tissue bulking or treating skin deficiencies are that they are either too fragile or too large to be injected, or too small and are digested or eliminated by the body.
Therefore, such particles all have one or more of the following limitations: (i) too large to be injected through a 30 gauge or smaller needle; (ii) particles of irregular shape clump together, making injection difficult; (iii) particles are too fragile, resulting in breakage during injection and digestion of the residues; (iv) injected particles are too small and are digested by macrophages or other components of the lymphatic system; and (v) injected particles are displaced as they do not adhere to the surrounding cells.
However, Teflon.RTM. particles have one or more of the following limitations: (1) the particles slide with the tissue and do not stay in place of injection; (2) the particles deform during and after injection, reducing the intended tissue bulking effect; and (3) the particles are digested or eliminated by the lymphatic system partly due to the fact that their diameters become smaller as a result of injection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

6.1 Example 1

Preparation Of Irregular Hydrogel Particles with Chemotactic Properties

[0138] 58 grams of sodium chloride and 27 grams of sodium acetate were dissolved at room temperature in 100 ml of demineralized water. To this solution 400 ml of glycerol were added, the pH was adjusted to 6.0 and monomers were then dissolved. More specifically to this solution 90 gram of methylolacrylamide, 2 g of methacrylamidopropyl-trimethylammonium-chlo-ride hydrochloride and 10 gram of N,N'-methylene-bis-acrylamide were added and the mixture was agitated until complete solubilization. The solution was heated at about 70.degree. C. and 100 ml of a solution of gelatin at a concentration of 500 mg / ml was added. The total volume of the mixture was then adjusted to 1000 ml by addition of demineralized water. Finally 20 ml of 70 mg / ml ammonium persulfate aqueous solution and 4 ml of N,N,N',N'-tertamethyl-ethylene-diamine was added. The obtained mixture was stored at 70.degree. C. for about 3 hours un...

example 2

6.2 Example 2

Preparation of Spherical Polyacrylic Hydrogel Gel Particles with Chemotactic Properties

[0140] The solution of monomers prepared as described in Example 1 above was poured slowly into 1500 ml of stirred and hot paraffin oil (50-70.degree. C.). After a few minutes a suspension / emulsion of liquids was obtained (the aqueous monomer solution was dispersed into oil and forms very small spherical droplets) and the polymerization occurred in suspension. The microdroplets were transformed into microbeads. The solid microbeads were recovered by centrifugation and suspended in 1 liter of physiological buffer containing 5% (w / v) glutaraldehyde and shaken for two hours. Finally the particles were extensively washed with water to eliminate completely the oil traces. Organic solvent extraction can be used for a more effective oil removal or an extensive washing in the presence of traces of nonionic detergents. The obtained microbeads are calibrated if necessary by sieving through a ny...

example 3

6.3 Example 3

Preparation of Hydrophilic Spherical Polystyrene Copolymer Particles Useful for Tissue Bulking

[0141] 10 gram of styrene is mixed with 60 ml of toluene. 1 gram of divinylbenzene, 1 gram of dimethyl-aminoethyl-methacrylate and 1 gram of dimethyl-acrylamide are added to the resulting solution. After complete solubilization the monomer solution is mixed with 1% of AIBN (2,2'-azobisisobutyronitrile) as a polymerization catalyst and with 40 ml of paraffin oil as a viscosity inducer agent. The mixture is poured in an agitated water solution containing 0.5% Tween 80. In this situation there is formation of droplet suspension which turns into solid microbeads when the temperature is raised to 80-90.degree. C. for three to five hours. The resulting beads are dried and organic solvents extracted. They are then swollen in an aqueous solution of collagen in phosphate buffer at neutral pH. Embedded collagen is then crosslinked with glutaraldehyde as described in Examples 1 and 2. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diametersaaaaaaaaaa
diametersaaaaaaaaaa
diametersaaaaaaaaaa
Login to View More

Abstract

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Description

[0001] This is a continuation-in-part application of U.S. patent application Ser. No. 09 / 263,773, filed Mar. 5, 1999.1. FIELD OF INVENTION[0002] The present invention relates to dermal augmentation and tissue bulking, particularly for the treatment of gastroesophageal reflux disease, urinary incontinence, urinary reflux disease, or skin contour deficiencies and wrinkles, using injectable microspheres.2. BACKGROUND OF INVENTION2.1 Gastroesophageal Reflux Disease ("GERD")[0003] Although gastroesophageal reflux is a normal physiological phenomenon, in some cases it is a pathophysiological situation that can result in a variety of symptoms which may become severe in extreme cases. Gastro-Esophageal Reflux Disease ("GERD"), describes a backflow of acidic and enzymatic liquid from the stomach to the esophagus. It causes burning sensations behind the sternum that may be accompanied by regurgitation of gastric acid into the mouth or even the lung. Complications of GERD which define the seve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/16A61K9/18A61K47/48A61K49/04A61L27/38A61L27/50A61L31/00A61L31/14
CPCA61K9/1635A61K9/1641A61K47/48869A61K47/48876A61K49/0442A61K49/048A61L2400/06A61L27/50A61L31/005A61L31/14A61K9/14A61K31/78A61K31/785A61L27/38A61K47/6925A61K47/6927A61K9/16A61K9/0019A61P1/04A61P13/00A61P17/02
Inventor VOGEL, JEAN-MARIETHOMAS, RICHARDBOSCHETTI, EGISTO
Owner BIOSPHERE MEDICAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products